HCC4006 Cells

HCC4006 is a human non-small cell lung cancer (NSCLC) cell line derived from a lung adenocarcinoma. It is characterized by an activating exon 19 deletion in the EGFR gene, which makes it particularly sensitive to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib. This feature has made HCC4006 a widely used model for studying EGFR-mutant NSCLC and resistance mechanisms to EGFR-targeted therapies. In the Cancer Cell Line Encyclopedia (CCLE), HCC4006 has been comprehensively profiled at the genomic, transcriptomic, and epigenetic levels, confirming its high sensitivity to EGFR inhibition and highlighting its use as a pharmacogenomic reference model. High-resolution genomic studies have revealed that HCC4006 displays a relatively simple karyotype compared to other NSCLC models, which may facilitate clearer interpretation of drug responses and genomic alterations. It lacks common resistance mutations such as T790M in the EGFR gene, making it suitable for modeling initial treatment responses. However, resistance can be induced in vitro, allowing researchers to study mechanisms of acquired resistance. For example, resistance to EGFR TKIs in HCC4006 has been linked to epithelial-mesenchymal transition (EMT) and activation of alternative signaling pathways, such as AXL kinase overexpression. HCC4006 has also been assessed in large-scale transcriptomic comparisons of cell lines and primary tumors. It is one of the lung adenocarcinoma cell lines that demonstrates a moderate correlation to primary tumor gene expression profiles, though the degree of correlation can vary depending on the purity of the tumor samples used for comparison. These analyses underscore the relevance of HCC4006 in modeling certain molecular aspects of lung adenocarcinoma, particularly those associated with EGFR-driven oncogenesis, while also emphasizing its limitations in fully recapitulating the heterogeneity of primary tumors.